Manko Joseph JR. Buys Shares of Myomo, Inc.

On June 25, 2026, Manko Joseph JR. acquired 78,704 shares of Myomo, Inc. (NYSE American: MYO). This insider purchase did not specify an average price or total value. The transaction was not conducted under a Rule 10b5-1 trading plan.

Insider Buying and Selling at Myomo, Inc.

Several insiders were active at Myomo, Inc. on June 25, 2026. Alongside Manko Joseph JR., Kirk Thomas and Crowley Thomas Aloysius JR. each purchased 78,704 shares. Earlier in the month, on June 12, 2026, David Henry, the Chief Financial Officer, sold 10,969 shares, while Chief Medical Officer Harry Kovelman and Chief Commercial Officer Micah Mitchell sold 10,442 and 9,061 shares, respectively, at an average price of $1.20 per share.

Myomo, Inc. Stock Down 33.6%

Shares of Myomo, Inc. traded near $1.14 on Saturday. The company, which operates in the medical devices industry, has a market cap of approximately $41.7 million. Myomo isn't currently profitable, with a forward P/E ratio unavailable due to negative earnings per share. The stock's beta is 1.46, indicating higher volatility compared to the market. Its 52-week range is from $0.60 to $2.38, with a 50-day moving average of $1.02 and a 200-day moving average of $0.92. The company maintains a current ratio of 2.734 and a quick ratio of 2.187, though it has a high debt-to-equity ratio of 210.649.

Analysts Set New Price Targets

On June 8, 2026, Ascendiant Capital maintained its 'buy' rating on Myomo, Inc. with a price target of $10.0. Analysts generally maintain a positive outlook on the stock, with a consensus 'buy' recommendation. The mean price target is $4.42, based on opinions from five analysts.

About Myomo, Inc.

Myomo, Inc. is a healthcare company based in Burlington, Massachusetts. It specializes in wearable medical robotics, designing and producing myoelectric orthotics for individuals with neuromuscular disorders. The company's flagship product, MyoPro, is a myoelectric-controlled upper limb brace that helps patients with weak or paralyzed arms perform daily activities. Myomo serves markets in the United States, Germany, and other regions, distributing products through orthotics and prosthetics providers, the Veteran's Administration, and other channels. Led by CEO Paul R. Gudonis, Myomo employs approximately 194 people.

Bottom Line

Insider purchases at Myomo, Inc. highlight ongoing interest in the company's prospects. Investors often track such activity as a potential indicator of insider confidence. However, it's important to remember that this information reflects past transactions and may not indicate current sentiment.